NervGen Pharma Corp. (NGENF)
USD 1.7
(-9.09%)
USD 1.7
(-9.09%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -11.29 Million | -17.78 Million | -8.26 Million | -6.3 Million | -8.09 Million | -1.04 Million |
| Net Income | -22.38 Million | -20.72 Million | -12.72 Million | -11.18 Million | -9.76 Million | -1.35 Million |
| Depreciation & Amortization | 145 Thousand | 115.11 Thousand | 42.62 Thousand | 39.64 Thousand | 38.22 Thousand | 19.76 Thousand |
| Deferred income taxes | -6.55 Million | -2.59 Million | - | - | - | - |
| Stock-based compensation | 6.04 Million | 2.77 Million | 4.01 Million | 3.41 Million | 1.29 Million | 37.94 Thousand |
| Change in working capital | -240.34 Thousand | 2.11 Million | 430.49 Thousand | 1.4 Million | 206.66 Thousand | 304.32 Thousand |
| Other non-cash items | 11.69 Million | 528.9 Thousand | -31.37 Thousand | 16.61 Thousand | 133.07 Thousand | -43.63 Thousand |
| Investing Cash Flow | -138.85 Thousand | -21.1 Thousand | -45.08 Thousand | -3421.00 | - | -126.81 Thousand |
| Investments in PPE | -141.4 Thousand | -21.1 Thousand | -45.08 Thousand | -3421.00 | - | -126.81 Thousand |
| Acquisitions | 2549.00 | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -133.23 | - | -42.34 | - | - | -126.82 |
| Financing Cash Flow | 766.28 Thousand | 22.64 Million | 19.61 Million | 7.84 Million | 9.83 Million | 3.59 Million |
| Debt repayment | -100.92 Thousand | -75.69 Thousand | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 867.21 Thousand | 19.76 Million | 18.9 Million | 8.7 Million | 10.74 Million | 3.59 Million |
| Other Financing Activities | 867.21 | 2.95 Million | 711.55 Thousand | -859.05 Thousand | -900.79 Thousand | 3591.47 |
| Accounts receivables | -223.18 Thousand | 36.97 Thousand | -1408.00 | 59.9 Thousand | -96.65 Thousand | -25.84 Thousand |
| Accounts payables | - | 2.32 Million | 318.73 Thousand | -165.08 Thousand | 242.57 Thousand | 273 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -17.16 Thousand | -242.33 Thousand | 113.17 Thousand | 1.51 Million | 60.75 Thousand | 57.16 Thousand |
| Cash at beginning of period | 22.45 Million | 16.92 Million | 5.59 Million | 4.1 Million | 2.47 Million | - |
| Cash at end of period | 11.65 Million | 22.45 Million | 16.92 Million | 5.59 Million | 4.1 Million | 2.47 Million |
| Capital Expenditure | -141.4 Thousand | -21.1 Thousand | -45.08 Thousand | -3421.00 | - | -126.81 Thousand |
| Effect of forex changes on cash | -123.89 Thousand | 686.57 Thousand | 31.37 Thousand | -46.82 Thousand | -113.4 Thousand | 49.76 Thousand |
| Net cash flow / Change in cash | -10.79 Million | 5.52 Million | 11.33 Million | 1.49 Million | 1.63 Million | 2.47 Million |
| Free Cash Flow | -11.43 Million | -17.8 Million | -8.31 Million | -6.31 Million | -8.09 Million | -1.16 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -7.82 Million | -2.34 Million | -8.6 Million | -22.38 Million | -4.3 Million | -4.76 Million |
| Depreciation & Amortization | 15.02 Thousand | 38.3 Thousand | 38.62 Thousand | 145 Thousand | 36.62 Thousand | 34.99 Thousand |
| Deferred income taxes | - | - | -1.69 Million | -6.55 Million | 1.02 Million | 142.6 Thousand |
| Stock-based compensation | 1.35 Million | 1.15 Million | 1.39 Million | 6.04 Million | 1.75 Million | 2.16 Million |
| Change in working capital | 415.56 Thousand | 174.85 Thousand | 293.53 Thousand | -240.34 Thousand | 59.22 Thousand | 419.09 Thousand |
| Other non-cash items | 3.24 Million | 2846.00 | 5.49 Million | 11.69 Million | 3506.00 | 3829.00 |
| Investing Cash Flow | 8411.00 | - | 1.00 | -138.85 Thousand | -138.45 Thousand | -2944.00 |
| Investments in PPE | - | - | - | -141.4 Thousand | -138.45 Thousand | -2944.00 |
| Acquisitions | - | - | 1.00 | 2549.00 | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 8411.00 | - | - | -133.23 | -135.78 | - |
| Financing Cash Flow | 111.27 Thousand | 22 Million | 74.76 Thousand | 766.28 Thousand | 72.38 Thousand | 253.86 Thousand |
| Debt repayment | -25.23 Thousand | -25.23 Thousand | -25.23 Thousand | -100.92 Thousand | -25.23 Thousand | -25.23 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 136.5 Thousand | 23.01 Million | 100 Thousand | 867.21 Thousand | 97.61 Thousand | 279.09 Thousand |
| Other Financing Activities | -27.44 Thousand | -1.6 Million | 100.00 | 867.21 | 97.61 | 279.09 |
| Accounts receivables | 2027.00 | 236.63 Thousand | -226.88 Thousand | -223.18 Thousand | 16.78 Thousand | 50.08 Thousand |
| Accounts payables | - | - | - | - | 202.11 Thousand | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 413.53 Thousand | -61.78 Thousand | 520.42 Thousand | -17.16 Thousand | -159.67 Thousand | 369.01 Thousand |
| Cash at beginning of period | 30.3 Million | 11.65 Million | 14.78 Million | 22.45 Million | 16.08 Million | 18.02 Million |
| Cash at end of period | 26.56 Million | 30.3 Million | 11.65 Million | 11.65 Million | 14.78 Million | 16.08 Million |
| Capital Expenditure | - | - | - | -141.4 Thousand | -138.45 Thousand | -2944.00 |
| Effect of forex changes on cash | 317.1 Thousand | -112.36 Thousand | -114.57 Thousand | -123.89 Thousand | 198.07 Thousand | -191 Thousand |
| Net cash flow / Change in cash | -3.74 Million | 18.64 Million | -3.12 Million | -10.79 Million | -1.29 Million | -1.93 Million |
| Free Cash Flow | -4.18 Million | -3.24 Million | -3.08 Million | -11.43 Million | -1.56 Million | -2 Million |
NBIX
STA
KWG
WHAUP
IES
PM-R